Your browser is no longer supported. Please, upgrade your browser.
MNOV MediciNova, Inc. daily Stock Chart
MNOV [NASD]
MediciNova, Inc.
Index- P/E- EPS (ttm)-0.30 Insider Own14.21% Shs Outstand49.60M Perf Week-22.60%
Market Cap236.10M Forward P/E- EPS next Y-0.56 Insider Trans0.00% Shs Float37.71M Perf Month-26.09%
Income-12.90M PEG- EPS next Q- Inst Own22.10% Short Float7.96% Perf Quarter-40.65%
Sales- P/S- EPS this Y16.00% Inst Trans-1.70% Short Ratio31.40 Perf Half Y-45.97%
Book/sh1.71 P/B2.78 EPS next Y0.00% ROA-16.50% Target Price20.00 Perf Year-44.91%
Cash/sh1.29 P/C3.70 EPS next 5Y20.00% ROE-17.40% 52W Range4.73 - 13.37 Perf YTD-29.38%
Dividend- P/FCF- EPS past 5Y4.70% ROI- 52W High-66.98% Beta1.38
Dividend %- Quick Ratio28.90 Sales past 5Y- Gross Margin- 52W Low-6.66% ATR0.26
Employees8 Current Ratio28.90 Sales Q/Q- Oper. Margin- RSI (14)20.12 Volatility5.97% 4.04%
OptionableYes Debt/Eq0.00 EPS Q/Q-814.50% Profit Margin- Rel Volume3.02 Prev Close4.76
ShortableYes LT Debt/Eq0.00 EarningsMar 06 AMC Payout- Avg Volume95.53K Price4.41
Recom2.00 SMA20-24.41% SMA50-31.83% SMA200-46.72% Volume216,960 Change-7.25%
Mar-25-19Resumed B. Riley FBR Buy $22
Mar-28-18Initiated B. Riley FBR, Inc. Buy $22
Apr-18-17Initiated Credit Suisse Outperform
Jan-04-13Reiterated Ladenburg Thalmann Buy $10.50 → $6
May-24-12Downgrade MLV & Co Buy → Hold
Oct-18-11Reiterated MLV Capital Buy $13 → $6
Jun-22-11Initiated Global Hunter Securities Buy $4
May-12-10Initiated Wedbush Outperform $13
Nov-12-08Reiterated Ladenburg Thalmann Buy $22 → $6
May-15-08Initiated Rodman & Renshaw Mkt Outperform $9
Jul-09-07Initiated Punk, Ziegel & Co Buy $22
Feb-25-20 08:15AM  MNOV: Multiple Trials of MN-166 Ongoing; Recent Price Move Creates Buying Opportunity Zacks Small Cap Research -7.25%
Feb-17-20 06:00PM  MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Japan GlobeNewswire
Jan-28-20 07:12AM  The Daily Biotech Pulse: Acceleron's Positive Data Readout, Surface Oncology Gets Nod For Pushing 2 Antibodies Into Clinics Benzinga
Jan-27-20 06:00PM  MediciNova Receives Notice of Intention to Grant for New Patent Covering MN-001 for the Treatment of Idiopathic Pulmonary Fibrosis in Europe GlobeNewswire
Dec-04-19 06:00PM  MediciNova Announces Additional Analyses from Completed Clinical Trial of MN-166 (ibudilast) in ALS Presented at the 30th International Symposium on ALS/MND in Perth, Australia GlobeNewswire
Nov-18-19 12:57PM  We're Not Worried About MediciNova's (NASDAQ:MNOV) Cash Burn Simply Wall St.
Nov-06-19 01:50PM  Here is What Hedge Funds Think About MediciNova, Inc. (MNOV) Insider Monkey
Oct-30-19 07:00PM  MNOV: Phase 3 Trial Initiated for MN-166 in ALS Zacks Small Cap Research
Oct-28-19 06:00AM  MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada GlobeNewswire
Oct-23-19 06:00AM  MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of NAFLD and NASH in Japan GlobeNewswire
Oct-07-19 07:00PM  MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Idiopathic Pulmonary Fibrosis in Japan GlobeNewswire
Sep-30-19 07:00PM  MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of Idiopathic Pulmonary Fibrosis in China GlobeNewswire
Sep-19-19 03:48PM  Does Market Volatility Impact MediciNova, Inc.'s (NASDAQ:MNOV) Share Price? Simply Wall St.
Sep-11-19 07:00PM  MediciNova to Present at the Ladenburg Thalmann 2019 Healthcare Conference in New York GlobeNewswire
Aug-29-19 07:00PM  MediciNova to Attend the Morgan Stanley Global Healthcare Conference in New York GlobeNewswire
Aug-14-19 10:30AM  MNOV: Abstract on MN-166 to be Presented at ALS/MND International Symposium Zacks Small Cap Research
Jul-30-19 07:00PM  MediciNova Announces MN-001 Research Collaboration with the National Cerebral and Cardiovascular Disease Research Center in Japan GlobeNewswire
Jul-29-19 07:00PM  MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 30th International Symposium on ALS/MND in Perth, Australia GlobeNewswire
Jul-24-19 11:00PM  MediciNova Appoints Kazuko Matsuda to its Board of Directors GlobeNewswire
Jul-18-19 04:00PM  MNOV: Readying for Phase 3 Trial in Multiple Sclerosis Zacks Small Cap Research
02:03PM  What Type Of Shareholder Owns MediciNova, Inc.'s (NASDAQ:MNOV)? Simply Wall St.
Jul-11-19 07:00PM  MediciNova Announces Phase 3 Clinical Trial Plan for MN-166 (ibudilast) in Progressive MS GlobeNewswire
Jun-12-19 07:00PM  MediciNova to Present at the JMP Securities Life Sciences Conference GlobeNewswire
Jun-05-19 07:00PM  MediciNova Announces Kick-off Meeting to Officially Launch Phase 3 Trial of MN 166 (ibudilast) in ALS GlobeNewswire
May-16-19 01:14PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by the Certain Officers and Directors of MediciNova, Inc. GlobeNewswire
May-15-19 07:00PM  MediciNova to Present at the 20th Annual B. Riley FBR Institutional Investor Conference GlobeNewswire
May-09-19 10:00AM  MNOV: Plans in Place for Phase 3 Trial in ALS Zacks Small Cap Research
May-08-19 07:23AM  If You Had Bought MediciNova (NASDAQ:MNOV) Stock Five Years Ago, You Could Pocket A 536% Gain Today Simply Wall St.
May-07-19 07:00PM  MediciNova Participated in the RECEDE Phase 3 Degenerative Cervical Myelopathy Trial Kick-off Meeting, DCM Symposium and the Official Launch of Myelopathy.org in London, United Kingdom GlobeNewswire
Apr-24-19 08:09AM  The Daily Biotech Pulse: FDA Greenlights AbbVie's Psoriasis Drug, Novartis Earnings, Patent Notification For MediciNova Benzinga
Apr-23-19 07:00PM  MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma GlobeNewswire +8.15%
Apr-16-19 08:10AM  The Daily Biotech Pulse: J&J Earnings, FDA Nod For Medicinova, Proteon To Explore Strategic Alternatives Benzinga
Apr-15-19 07:00PM  MediciNova Announces Plans to Move Forward with a Phase 3 Trial of MN-166 (ibudilast) in ALS GlobeNewswire
Apr-08-19 09:45AM  MNOV: New Analysis Shows Efficacy of MN-166 in Non-Relapsing SPMS Zacks Small Cap Research
Apr-03-19 07:00PM  MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in China GlobeNewswire
Apr-01-19 07:00PM  MediciNova Announces Results of Subgroup Analysis from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS GlobeNewswire
Mar-24-19 07:00PM  MediciNova Announces Upcoming Presentations Regarding the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive Multiple Sclerosis at the 71st American Academy of Neurology Annual Meeting in Philadelphia, Pennsylvania GlobeNewswire
Mar-05-19 06:51PM  MediciNova Announces MN-001 Research Collaboration with The Jikei University School of Medicine in Tokyo, Japan GlobeNewswire
Feb-28-19 06:00PM  MediciNova Announces the Publication of Results of the Animal Model Study of MN166 (ibudilast) in Glioblastoma in Scientific Reports GlobeNewswire
Feb-20-19 10:00AM  MNOV: Continuing to Plan for Phase 3 Studies in Progressive MS and ALS Zacks Small Cap Research
Feb-12-19 01:30PM  One Thing To Remember About The MediciNova, Inc. (NASDAQ:MNOV) Share Price Simply Wall St.
Jan-21-19 06:00PM  MediciNova Receives Notice of Allowance for New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) and other Neurodegenerative Diseases GlobeNewswire
Jan-09-19 07:39AM  The Daily Biotech Pulse: BioMarin Trims Outlook, MediciNova Enrolls First Patient In Brian Cancer Drug Study Benzinga
Jan-08-19 06:00PM  MediciNova Announces Initiation of Enrollment in a Clinical Trial of MN-166 (ibudilast) in Glioblastoma GlobeNewswire +9.13%
Jan-07-19 06:00PM  MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis in Japan GlobeNewswire
Dec-12-18 10:06AM  Do Insiders Own Lots Of Shares In MediciNova, Inc. (NASDAQ:MNOV)? Simply Wall St. +6.69%
06:00AM  MediciNova to Present at the J.P. Morgan Healthcare Conference in San Francisco GlobeNewswire
Oct-31-18 10:00AM  MNOV: MN-166 to be Studied in Degenerative Cervical Myelopathy Zacks Small Cap Research +5.29%
Oct-05-18 08:35AM  The Daily Biotech Pulse: MediciNova Gets Orphan-Drug Status, KemPharm To Offer Shares, Emergent Buys Vaccine Maker Benzinga
Oct-04-18 07:00PM  MediciNova Announces FDA Grants Orphan Drug Designation to MN-166 (ibudilast) for Glioblastoma GlobeNewswire
Sep-28-18 09:45AM  MNOV: Positive FDA Feedback on ALS Phase 3 Plan Zacks Small Cap Research
Sep-25-18 07:00PM  MediciNova Announces Positive FDA Feedback Regarding Phase 3 Plan for MN-166 (ibudilast) in ALS GlobeNewswire
Sep-18-18 07:00PM  MediciNova to Present at the Ladenburg Thalmann 2018 Healthcare Conference in New York GlobeNewswire
Sep-04-18 07:00PM  MediciNova to Attend the Morgan Stanley Global Healthcare Conference in New York GlobeNewswire
Aug-29-18 05:00PM  MediciNova Announces the Publication of Results of the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS in the New England Journal of Medicine GlobeNewswire +5.40%
Aug-20-18 07:00PM  National Institute on Alcohol Abuse and Alcoholism Awards R01 Research Grant to UCLA for Phase 2b Clinical Trial of MediciNova's MN-166 (ibudilast) in Alcohol Use Disorder GlobeNewswire
07:50AM  Report: Exploring Fundamental Drivers Behind MediciNova, Dermira, FRP, BiondVax Pharmaceuticals, The Descartes Systems Group, and American Software New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Aug-06-18 07:00PM  MediciNova Announces Initiation of NIHR Grant-Funded Phase 2/3 Trial of MN-166 (ibudilast) for the Treatment of Degenerative Cervical Myelopathy in Collaboration with the University of Cambridge GlobeNewswire
Jul-31-18 07:00PM  MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 29th International Symposium on ALS/MND in Glasgow, Scotland, UK GlobeNewswire
Jul-29-18 07:00PM  MediciNova Announces Full Enrollment in ALS Biomarker Clinical Trial GlobeNewswire
Jul-25-18 09:15AM  MNOV: Plenty of Cash to Advance Pipeline Forward Zacks Small Cap Research
Jul-12-18 09:30AM  MNOV: Encouraging Data from Subgroup Analysis of ALS Study Zacks Small Cap Research
Jul-09-18 07:00PM  MediciNova Announces Clinical Data from Subgroup Analyses of Completed Clinical Trial of MN-166 (ibudilast) in ALS GlobeNewswire
Jun-19-18 07:00PM  MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of Hypertriglyceridemia and Hypercholesterolemia in Japan GlobeNewswire
Jun-05-18 07:35AM  Detailed Research: Economic Perspectives on Galapagos NV, Cellectis S.A, MediciNova, Logitech International S.A, The Descartes Systems Group, and Canadian Pacific Railway What Drives Growth in Today's Competitive Landscape GlobeNewswire
May-31-18 07:14PM  When Will MediciNova Inc (NASDAQ:MNOV) Become Profitable? Simply Wall St.
May-16-18 03:55PM  Want To Invest In MediciNova Inc (NASDAQ:MNOV)? Heres How It Performed Lately Simply Wall St.
May-09-18 07:00PM  MediciNova Announces Opening of Investigational New Drug Application for MN-166 (ibudilast) in Glioblastoma GlobeNewswire
May-08-18 07:00PM  MediciNova to Present at the UBS Global Healthcare Conference in New York GlobeNewswire
May-07-18 07:00PM  MediciNova Announces Plans to Collaborate with UCLA Researchers in Grant-Funded Clinical Trial of MN-166 (ibudilast) in Alcohol Use Disorder and Withdrawal GlobeNewswire
May-01-18 09:20AM  MNOV: Additional Data Presented for MN-166 in MS and ALS Zacks Small Cap Research
Apr-26-18 07:00PM  MediciNova Announces Additional Data from Completed Clinical Trial of MN-166 (ibudilast) in ALS Presented at the American Academy of Neurology (AAN) 70th Annual Meeting GlobeNewswire
Apr-24-18 06:30AM  MediciNova Announces the Presentation of the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS at the American Academy of Neurology (AAN) 70th Annual Meeting Plenary Session with Additional Imaging Data GlobeNewswire -5.05%
Apr-13-18 08:30AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
06:30AM  MediciNova Announces Presentation of Significant Positive Results from Interim Analysis of the Phase 2 Trial of MN-001 (tipelukast) in NASH / NAFLD at the International Liver Congress 2018 in Paris, France GlobeNewswire
Apr-12-18 08:20AM  Recent Analysis Shows Landmark Infrastructure Partners LP, Laureate Education, MDC Partners, Pzena Investment Management, Dermira, and MediciNova Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Apr-06-18 12:55PM  The Week Ahead In Biotech: PDUFA Dates, IPOs And More Benzinga
Apr-03-18 07:20AM  Wired News MediciNova Released Results of Phase-2 Clinical Trial Assessing MN-166 (ibudilast) in Methamphetamine Dependence ACCESSWIRE
Apr-02-18 04:30PM  Why Limelight Networks, MediciNova, and Commvault Systems Jumped Today Motley Fool +18.88%
02:53PM  Here's Why MediciNova Jumped as Much as 26.2% Today Motley Fool
10:04AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
Apr-01-18 07:00PM  MediciNova Announces Phase 2 Trial of MN-001 (tipelukast) in NASH / NAFLD will be Terminated Early based on Significant Positive Results from Interim Analysis GlobeNewswire
Mar-29-18 06:30AM  MediciNova Announces Results of Phase 2 Clinical Trial of MN-166 (ibudilast) in Methamphetamine Dependence GlobeNewswire -14.55%
Mar-28-18 07:00PM  MediciNova Announces Collaboration with the University of Sydney Concord Cancer Centre to Evaluate MN-166 (ibudilast) in Chemotherapy-Induced Peripheral Neuropathy GlobeNewswire
Mar-15-18 08:15AM  Report: Exploring Fundamental Drivers Behind Reading International, Rhythm Pharmaceuticals, Grupo Aeroportuario del Centro Norte S.A.B. de C.V., Golar LNG, Central European Media Enterprises, and MediciNova New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Mar-12-18 07:00PM  MediciNova to Participate in Business Development Panel Session at the BIO Asia International Conference in Tokyo GlobeNewswire
Feb-21-18 06:18PM  Is MediciNova Inc (NASDAQ:MNOV) A Good Healthcare Bet? Simply Wall St.
Feb-18-18 06:00PM  MediciNova Announces Upcoming Presentation of the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS at the American Academy of Neurology (AAN) 70th Annual Meeting in Los Angeles, California GlobeNewswire
Feb-16-18 10:30AM  MNOV: Raises $40 Million in Underwritten Public Offering Zacks Small Cap Research
Feb-12-18 06:30PM  MediciNova Announces Closing of Underwritten Public Offering of Common Stock GlobeNewswire
Feb-08-18 01:17PM  Here's Why MediciNova, Inc. Stock Is Sliding Today Motley Fool
Feb-07-18 07:12PM  MediciNova Announces Pricing of Underwritten Public Offering of Common Stock GlobeNewswire
04:01PM  MediciNova Announces Proposed Underwritten Public Offering of Common Stock GlobeNewswire
10:00AM  MNOV: MN-166 Shows 26% Reduction in Disability Progression in Progressive MS Phase 2 Study Zacks Small Cap Research
Feb-05-18 07:00AM  Blog Exposure - MediciNovas MN-166 Shows Reduction in Confirmed Disability Progression in SPRINT-MS Phase-2b Trial ACCESSWIRE
Feb-01-18 06:00PM  MediciNova Announces MN-166 (ibudilast) Demonstrated a 26% Reduction in Confirmed Disability Progression in the SPRINT-MS Phase 2b Trial in Progressive MS: Potential Best-in-Disease Drug GlobeNewswire
Jan-31-18 07:00AM  MediciNova Announces Presentation of the SPRINT-MS Phase 2b Study of MN-166 (ibudilast) in Progressive MS at the ACTRIMS Forum on February 1, 2018 in San Diego GlobeNewswire
Jan-30-18 06:00PM  MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the American Academy of Neurology (AAN) 70th Annual Meeting in Los Angeles, California GlobeNewswire
Jan-28-18 06:00PM  MediciNova Announces MN-001 (tipelukast) NASH/NAFLD Phase 2 Trial Interim Results Selected for Presentation at the International Liver Congress 2018 in Paris, France GlobeNewswire
Jan-16-18 06:00PM  MediciNova to Present at the 98th Annual Meeting of the Chemical Society of Japan GlobeNewswire
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. MediciNova, Inc. was founded in 2000 and is headquartered in La Jolla, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Matsuda KazukoChief Medical OfficerJun 12Option Exercise4.8037,000177,600109,457Jun 13 05:06 PM
Nagao HidekiDirectorMay 13Option Exercise2.771,0002,7701,000May 14 04:41 PM
Okajima MasatsuneVP and Head of Japanese OfficeFeb 28Option Exercise4.19886,9503,718,7631,040,530Mar 04 06:00 AM